Equity Overview
Price & Market Data
Price: $0.275
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $89,767,488
Volume: 0
Performance Metrics
1 Week: 26.68%
1 Month: 26.68%
3 Months: 14.16%
6 Months: -47.04%
1 Year: -78.01%
YTD: 26.68%
Company Details
Employees: 139
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Norway
Details
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.